Oxford BioMedica PLC (OXB)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
167.00p
Buy
450.00p
11.50p (+3.44%)
Prices updated at 05 Jun 2025, 07:15 BST
| Prices minimum 15 mins delay
Prices in GBX
Oxford BioMedica PLC is a biopharmaceutical company based in the United Kingdom. It develops gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Roch F. Doliveux
CEO
Dr. Frank Mathias
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
861
Head office
Windrush Court
Oxford
United Kingdom
OX4 6LT
Key personnel
Owner name | Salary |
|---|---|
Mr. Stuart Henderson Non-Executive Director, Vice Chairman | - |
Professor Dame Kay Davies Non-Executive Director, Senior Independent Director | - |
Dr. Roch F. Doliveux Non-Executive Director, Chairman | - |
Dr. Heather Elizabeth Preston, M.D. Non-Executive Director | - |
Ms. Namrata P Patel Non-Executive Director | - |
Ms. Lucinda Crabtree Executive Director, Chief Financial Officer | - |
Dr. Frank Mathias Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| M&G Investment Management Limited | 5,734,008 |
| M&G Recovery Fund | 4,992,624 |
| Liontrust Fund Partners LLP | 2,109,786 |
| Zurich Ltd. | 1,866,446 |
| BlackRock Smaller Companies | 1,817,295 |
Director dealings
Date | Action |
|---|---|
| No data | |
Please note that past performance is not a reliable indicator of future returns.
